Predict your next investment

Corporation
HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
sb.com

See what CB Insights has to offer

Investments

6

Portfolio Exits

4

About SmithKline Beecham

SmithKline Beecham is a corporation based out of Philadelphia, Pennsylvania.On August 1st, 1999, SmithKline Beecham was acquired by Quest Diagnotics at a valuation of $1.3B.

SmithKline Beecham Headquarter Location

One Franklin Plaza

Philadelphia, Pennsylvania, 19101,

United States

(800)366-8900

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest SmithKline Beecham News

Alembic Pharmaceuticals' joint venture Aleor gets USFDA approval to market Mupirocin cream

Nov 17, 2021

The approved abbreviated new drug application (ANDA) for Mupirocin cream is therapeutically equivalent to the reference listed drug product (RLD), Bactroban cream (2 per cent) of SmithKline Beecham (Cork) Ltd, Ireland, the company said. Mupirocin cream is indicated for the treatment of secondarily infected traumatic skin lesions due to susceptible strains of S aureus and S pyogenes. Source: Website Alembic Pharmaceuticals on Wednesday said its joint venture Aleor Dermaceuticals Ltd (Aleor) has received approval from the US health regulator to market Mupirocin cream. The approved abbreviated new drug application (ANDA) for Mupirocin cream is therapeutically equivalent to the reference listed drug product (RLD), Bactroban cream (2 per cent) of SmithKline Beecham (Cork) Ltd, Ireland, the company said. See Zee Business Live TV Streaming Below: Mupirocin cream is indicated for the treatment of secondarily infected traumatic skin lesions due to susceptible strains of S aureus and S pyogenes. Aleor has been granted a competitive generic therapies (CGT) designation for this ANDA and it is eligible for 180 days of exclusivity as it is the first approved applicant, Alembic Pharmaceuticals said in a statement. According to IQVIA, Mupirocin cream USP, 2 per cent has an estimated market size of USD 28 million for the twelve months ended June 2021.

SmithKline Beecham Investments

6 Investments

SmithKline Beecham has made 6 investments. Their latest investment was in Antex Biologics as part of their Series A on April 4, 1995.

CBI Logo

SmithKline Beecham Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/19/1995

Series A

Antex Biologics

$3.5M

Yes

D.H. Blair, and Undisclosed Investors

1

11/26/1990

Series B

Subscribe to see more

$99M

Subscribe to see more

10

6/29/1988

Series A

Subscribe to see more

$99M

Subscribe to see more

10

2/1/1986

Seed

Subscribe to see more

$99M

Subscribe to see more

10

10/1/1985

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/19/1995

11/26/1990

6/29/1988

2/1/1986

10/1/1985

Round

Series A

Series B

Series A

Seed

Series A

Company

Antex Biologics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$3.5M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

D.H. Blair, and Undisclosed Investors

Sources

1

10

10

10

10

SmithKline Beecham Portfolio Exits

4 Portfolio Exits

SmithKline Beecham has 4 portfolio exits. Their latest portfolio exit was Antex Biologics on December 01, 1995.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/1/1995

IPO

1

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

12/1/1995

00/00/0000

00/00/0000

00/00/0000

Exit

IPO

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

SmithKline Beecham Team

5 Team Members

SmithKline Beecham has 5 team members, including former Executive Vice President, Jerry Karabelas.

Name

Work History

Title

Status

Jerry Karabelas

Executive Vice President

Former

Vijay Aggarwal

Senior Vice President

Former

Tamar Howson

Lexicon Pharmaceuticals, Bristol-Myers Squibb, Johnston Associates, and Care Capital

Senior Vice President

Former

Brian Metcalf

Marion Merrell Dow, and Incyte

Senior Vice President

Former

Amber Salzman

Senior Vice President

Former

Name

Jerry Karabelas

Vijay Aggarwal

Tamar Howson

Brian Metcalf

Amber Salzman

Work History

Lexicon Pharmaceuticals, Bristol-Myers Squibb, Johnston Associates, and Care Capital

Marion Merrell Dow, and Incyte

Title

Executive Vice President

Senior Vice President

Senior Vice President

Senior Vice President

Senior Vice President

Status

Former

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.